Breadcrumb Home Business activities Âé¶¹Éç BioCapital Âé¶¹Éç BioCapital Portfolio DBV Technologies DBV Technologies Develops patches for desensitization of food allergy using epicutaneous delivery. The lead program is in late stage clinical trials for peanut allergy desensitization. Âé¶¹Éç BioCapital Invested 2010 IPO in 2013 – DBV (Euronext Paris) Location Bagneux, Ill-de-France, France